Watch for the FDA end-of-Phase 2 meeting outcome and any updates on partnering discussions. The stock may re-rate on confirmation of a regulatory path or deal interest. Follow-up data in Q2 2026 could catalyze further momentum.
Price Chart
Executive Summary
Medicus Pharma (MDCX) announced positive topline results from its Phase 2 SKNJCT-003 trial of D-MNA, a microneedle patch for treating basal cell carcinoma. The 200μg dose showed 73% clinical clearance and 40% histological clearance at Day 57, supporting plans for an FDA end-of-Phase 2 meeting and potential partnering. The data are preliminary but represent the first efficacy signal in a controlled trial for this non-invasive approach.
Key Facts
- Phase 2 SKNJCT-003 trial met primary efficacy endpoints with dose-dependent response, especially in the 200μg cohort.
- At Day 57, 200μg D-MNA achieved 73% clinical clearance and 40% histological clearance vs. 38% and 38% in placebo.
- Results support planned end-of-Phase 2 FDA meeting in H1 2026 and may accelerate partnering discussions.
- Final Clinical Study Report with full safety data expected in Q2 2026; no material changes to efficacy anticipated.
- Study was not powered for registrational approval, so results are proof-of-concept, not definitive.
Financial Impact
Potential near-term valuation inflection for a $29M market cap biotech; de-risking of SkinJect program could attract partnerships or licensing deals.
Risk Factors
- Final safety data or full Clinical Study Report could reveal adverse events that impact development plans.
- Study not powered for registration; larger pivotal trials will be required for approval.
- Market cap remains small and volatile; results may not lead to immediate commercial or partnership traction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.60 | awaiting T+1 | — | $2.51 (−3.46%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 16, 2026 10d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 7, 2026 19d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.51 (+2363.20%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.51 (+1475.64%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.51 (−1443.67%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.51 (+1455.14%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.51 (+1372.14%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.51 (+518.23%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.51 (−733.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers